Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
Continue Reading
-
Noosa News22 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business24 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
Business20 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News18 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland